Enterprise Value
362.7M
Cash
297.5M
Avg Qtr Burn
-12.55M
Short % of Float
8.49%
Insider Ownership
2.10%
Institutional Own.
93.61%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
TERN-501 (THR-B Agonist) +TERN-101 (FXR agonist) Details Non-alcoholic steatohepatitis Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2a Data readout | |
TERN-101 (FXR agonist) Details Non-alcoholic steatohepatitis | Phase 2a Update | |
TERN-201 (VAP-1 inhibitor) Details Non-alcoholic steatohepatitis | Phase 1b Update | |
Phase 1 Data readout | ||
TERN-701 (Allosteric BCR-ABL inhib) Details Chronic myelomonocytic leukemia | Phase 1 Interim update |